Pharma continues to get poor grades when it comes to sharing clinical trial data

“Will “poor grades” alone add “further pressure on the pharmaceutical industry to improve disclosure practices”? Incentives, policing, and regulation, along with making a positive argument that sways manufacturers, are still needed.”